Compare GDL & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDL | XTNT |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 86.2M |
| IPO Year | N/A | 2009 |
| Metric | GDL | XTNT |
|---|---|---|
| Price | $8.53 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 11.3K | ★ 153.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | N/A | $15.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.71 | $0.34 |
| 52 Week High | $8.67 | $0.95 |
| Indicator | GDL | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 39.07 |
| Support Level | $8.38 | $0.55 |
| Resistance Level | $8.62 | $0.68 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 69.01 | 29.09 |
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.